Triple monoamine reuptake inhibitor

This page covers all Triple monoamine reuptake inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT).

Targets

Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)

Phase 3 pipeline (1)

• Centanafadine SR · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry / Neurology
  Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine.

Patent intelligence

• triple monoamine reuptake inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates